Estimates suggest that needle biopsy would diagnose 32% of them with prostate cancer. ... Many contemporary men receiving treatment for localized prostate cancer are unlikely to benefit from the intervention,” the authors wrote.
Cabazitaxel (Jevtana), a chemotherapy drug used with prednisone for prostate cancer. ... It is the first treatment for advanced, hormone-refractory prostate cancer that has worsened during or after treatment with docetaxel.
found. Decision aids improved participants' informed decision making about prostate cancer screening but did not change the actual screening rates, a study found. ... one month and 13 months for prostate cancer knowledge, decisional conflict, decisional
Prostate cancer mortality varied according to disease risk but not by number of comorbid conditions. ... 3.3), respectively, in the subhazard of prostate cancer mortality compared with those treated aggressively.
Radical prostatectomy was associated with fewer deaths from prostate cancer compared to watchful waiting, a Scandinavian study found. ... Two large, randomized, controlled trials are under way to determine whether treatment will reduce mortality in men
An expanded approval of abiraterone acetate (Zytiga) to treat metastatic castration-resistant prostate cancer prior to chemotherapy. ... The drug was initially approved in November 2011 for use in patients whose prostate cancer progressed after treatment
The primary outcome of this study was prostate cancer mortality at a median of 10 years of follow-up. ... An accompanying editorial for both studies stated that active monitoring, as compared with treatment of early prostate cancer, leads to increased
Sipuleucel-T (Provenge), autologous cellular immunotherapy approved to treat asymptomatic or minimally symptomatic prostate cancer that has spread to other parts of the body and is resistant to standard hormone treatment. ... cancer. Most of the studies
31, 2015. The study's primary outcomes were prostate cancer-specific mortality and mortality from other causes. ... Hazard ratios for prostate cancer mortality did not appear to vary substantially by clinical stage or primary therapy.
In addition, screening programs may prevent approximately three cases of metastatic prostate cancer per 1,000 men screened. ... While PSA is an imperfect tumor marker, it is currently the most widely offered and studied prostate cancer screening test.